There are 412 resources available
119P - HER2+ early-stage breast cancer treated with extended adjuvant neratinib in the context of the European Early Access Program: NEAR study final results
Presenter: Tajana Silovski
Session: Lunch and Poster Display session
120P - Impact of PET-CT and neoadjuvant systemic treatment in patients with stage I HER2+ breast cancer
Presenter: Josefien van Olmen
Session: Lunch and Poster Display session
121P - Endocrine response assessment in HR+ HER2- early breast cancer: Concordance of central versus local Ki67 measurements in the ADAPTcycle trial
Presenter: Moritz Hamann
Session: Lunch and Poster Display session
122P - Primary results and biomarker analysis from PREDIX LumB: A prospective randomized phase II trial investigating sequence of neoadjuvant chemotherapy and palbociclib/endocrine therapy for luminal breast cancer
Presenter: Alexios Matikas
Session: Lunch and Poster Display session
123P - Goserelin 10.8 mg and 3.6 mg depots in breast cancer (BC): A large real-world noninferiority study
Presenter: yongsheng wang
Session: Lunch and Poster Display session
124P - Neoadjuvant durvalumab plus endocrine therapy following immune-attractant exposure for early-stage ER+/HER2- breast cancer
Presenter: Benjamin Verret
Session: Lunch and Poster Display session
125P - Suboptimal ovarian suppression during adjuvant endocrine therapy for premenopausal women with breast cancer: An exploratory analysis of the PREFER and GIM 23 studies
Presenter: Simone Nardin
Session: Lunch and Poster Display session
126P - A randomized controlled trial (RCT) comparing optimal local treatment with or without endocrine therapy (ET) in patients (pts) aged =70 with lower risk breast cancer (BC) [REaCT-70 Study]
Presenter: Marie-France Savard
Session: Lunch and Poster Display session
127P - Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial
Presenter: Jens Huober
Session: Lunch and Poster Display session
129P - Adherence to adjuvant endocrine therapy in the era of combination treatments: A population-based study
Presenter: Louise Eriksson Bergman
Session: Lunch and Poster Display session